

Published in final edited form as:


*Org Lett.* 2009 February 19; 11(4): 899–902. doi:10.1021/ol802844z.

## Synthesis of Amidines Using *N*-Allyl Ynamides. A Palladium-Catalyzed Allyl Transfer Through an Ynamido- $\pi$ -Allyl Complex

Yu Zhang, Kyle A. DeKorver, Andrew G. Lohse, Yan-Shi Zhang, Jian Huang, and Richard P. Hsung\*

Division of Pharmaceutical Sciences and Department of Chemistry, University of Wisconsin, Madison, WI 53705

### Abstract



A *de novo* transformation of *N*-allyl-*N*-sulfonyl ynamides to amidines is described featuring a palladium-catalyzed *N*-to-*C* allyl transfer via ynamido-palladium- $\pi$ -allyl complexes.

Our involvement in the studies of Huisgen's azide-[3 + 2]<sup>1–3</sup> cycloadditions employing ynamides<sup>4–7</sup> led us to an exciting possibility. As shown in Scheme 1, under copper(I)-catalyzed conditions,<sup>8</sup> while triazolyl copper intermediates **1** could be trapped with electrophiles other than proton to afford more substituted triazoles **2**,<sup>9,10</sup> when R<sup>2</sup> = Ts, it could also readily lose N<sub>2</sub> in a retro-[3 + 2] manner to give ynamido-copper complexes **3a** in equilibrium with ketenimine-copper complexes **3b**. A series of elegant studies have since appeared reporting nucleophilic trappings of **3** in both inter- and intramolecular fashion, leading to amidines and amidates.<sup>11–14</sup> The potential of harvesting new reactivities from ynamido-metal complexes captured our attention. Consequently, we examined a different pathway that can provide general access to ynamido-metal  $\pi$ -allyl complexes **5a** and **5b** from *N*-allyl-*N*-sulfonyl ynamides **4**. We report here a *de novo* synthesis of pharmacologically useful amidines<sup>15–18</sup> from ynamides featuring a palladium-catalyzed *N*-to-*C* allyl transfer through ynamido- $\pi$ -allyl complexes.

While identifying a suitable palladium catalyst for our intended reaction pathway was not difficult, we found two amidine products. As shown in Table 1, when treating *N*-allyl-*N*-sulfonyl ynamide **6** with 5 mol% of Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> in the presence of *c*-hex-NH<sub>2</sub> in THF at 65 °C, both amidines **7** and **8** were observed.<sup>19</sup> Intriguingly, the ratio of **7** and **8** depended upon the amount of *c*-hex-NH<sub>2</sub> that was used. A greater amount of *c*-hex-NH<sub>2</sub> [3–5 equiv] predominantly led to the formation of **7** in which the allyl group is lost [entries 1 and 2], while 1.0 equiv of *c*-hex-NH<sub>2</sub> and/or addition with the use of syringe pump began to favor the formation of **8** in which the allyl group had undergone an *N*-to-*C* transfer [entries 3 and 4].

Moreover, a quick screening of palladium sources revealed that the allyl transfer is catalyst dependent [Table 1]. At 3.0 equiv of *c*-hex-NH<sub>2</sub> in comparison with Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> [see entry 1], Pd(PPh<sub>3</sub>)<sub>4</sub> gave exclusively allyl transferred amidine **8** [entry 5], while Pd(dppe)Cl<sub>2</sub> and Pd(dppf)Cl<sub>2</sub> [entries 6 and 7] reverted back to favor amidine **7** with Pd(dppf)Cl<sub>2</sub> giving a better yield [entry 7]. Sensing that these contrasts could be due to the differences either in the initial oxidation state of the palladium metal, or more likely, their respective ligands, we examined Pd<sub>2</sub>(dba)<sub>3</sub> along with 10 mol% of various phosphine ligands. While BINAP was not useful [entry 8, potential *ee* was not analyzed], we found that both xantphos<sup>20</sup> and X-phos<sup>21</sup> [entries 9 and 10] represent excellent ligand systems for promoting the allyl transfer, with the former phosphine ligand [see entry 9] providing a much faster reaction.

The generality of this allyl transfer could be established very quickly via three perspectives, leading to the synthesis of a diverse array of amidines. First, we employed a range of primary amines including allyl amine [entry 3 in Table 2], propargyl amine [entry 4], and anilines [entries 5–9]. Secondly, we examined a series of secondary amines including the use of *p*-Ns-substituted ynamide [see **20** in Figure 1], indoline [see **26**], tetrahydroquinoline [see **27**], and imidazole [see **28**].

Thirdly, we explored ynamides **29a–c** with variations on the acetylenic substituent [Table 3]. It is noteworthy that while Pd(PPh<sub>3</sub>)<sub>4</sub> was effective in promoting allyl transfer when using primary amines, it was not useful for secondary amines [with the exception of **22**] and only the usage of Pd<sub>2</sub>(dba)<sub>3</sub> and xantphos led to allyl transferred amidines.

A proposed model consistent with our observations is shown in Scheme 2. While all evidence points toward the presence of ynamido-Pd- $\pi$ -allyl complexes **5a** in equilibrium with the ketenimine complex **5b** through an oxidative addition,<sup>22,23</sup> the pathway clearly diverged thereafter depending upon the concentration of the amine HNR<sub>2</sub> and the nature of the ligand. We believe the first equivalent of HNR<sub>2</sub> effectively gave the amidinyl Pd- $\pi$ -allyl complexes **31a** and **31b** via nucleophilic addition to **5b**. An ensuing reductive elimination of **31a** and/or **31b** would lead to respective allyl transferred amidines **32a** and **32b**, and **32a** appears to tautomerize favorably to **32b**.

However, this reductive elimination step appears to be less favored when an excess of amine was used. Consequently, Pd-complexes **33** could be attained likely through a direct nucleophilic attack on the Pd- $\pi$ -allyl motif, thereby leading to the loss of the respective allyl amines,<sup>24</sup> and ultimately, the formation of the non-allyl transferred amidines **34** after reductive elimination. In addition, this de-allylative pathway is also consistent with the fact that when using the more nucleophilic secondary amines [relative to primary amines]<sup>25</sup> and Pd(PPh<sub>3</sub>)<sub>4</sub>, non-allyl transferred amine product predominated. Consequently, in all cases, either a controlled amount of HNR<sub>2</sub>, or a slow addition of HNR<sub>2</sub>, or more bulky ligands such as X-phos<sup>21</sup> and/or bidentate ligands with unique bite angles such as xantphos<sup>20,26</sup> that presumably promote reductive elimination could be employed to favor the formation of allyl transferred amidines **32b**.

Finally, the efficacy of oxidative addition likely plays a role in the distribution between non-allyl and allyl transferred amidines because the choice of Pd(0) source appears to be critical. Specifically, a Pd(II) source could also serve as  $\pi$ -Lewis acid to activate the ynamide, leading to keteniminium Pd-complex **35** [Scheme 3]. After addition of the first equivalent of HNR<sub>2</sub>, de-allylation of the resulting *N*-allyl enamide **36** could take place with a second equivalent of HNR<sub>2</sub>. This process could be promoted by either Pd(0) or Pd(II), with the former initiating an oxidative addition while the latter again serving to activate the ketene-aminal motif. This assessment is consistent with the observation that non-allyl transferred amidines **34** were the major product when using Pd(II) sources.

We have described here a *de novo* transformation of *N*-allyl-*N*-sulfonyl ynamides to a diverse array of amidines featuring a palladium-catalyzed *N*-to-*C* allyl transfer via ynamido-palladium- $\pi$ -allyl complexes. Efforts in further developing synthetic methods involving these ynamido-palladium- $\pi$ -allyl complexes are underway.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgement


We thank NIH [GM066055] for funding.

## References

1. (a) Huisgen R. *Angew Chem* 1963;75:604. Huisgen, R. 1,3-Dipolar Cycloaddition Chemistry. Padwa, A., editor. Oxford: Pergamon Press; 1984. p. 1-176.
2. For leading reviews, see: (a) Meldal M, Tornøe CW. *Chem. Rev* 2008;108:2952. [PubMed: 18698735] (b) Wu P, Fokin VV. *Aldrichimica Acta* 2007;40:7. (c) Bock VD, Hiemstra H, Van Maarseveen JH. *Eur. J. Org. Chem* 2006:51. (d) Katritzky AR, Zhang Y, Singh SK. *Heterocycles* 2003;60:1225. (e) Abu-Orabi ST. *Molecule* 2002;7:302. (f) Kolb HC, Finn MG, Sharpless KB. *Angew. Chem., Int. Ed* 2001;40:2004.
3. For a review on organic azides, see: Bräse S, Gil C, Knepper K, Zimmermann v. *Angew. Chem., Int. Ed* 2005;44:5188.
4. (a) Zhang X, Li H, You L, Tang Y, Hsung RP. *Adv. Syn. Cat* 2006;348:2437. (b) Zhang X, Hsung RP, You L. *Org. Biomol. Chem* 2006;6:2679. [PubMed: 16826290]
5. For reviews on ynamides, see: (a) Zifcick CA, Mulder JA, Hsung RP, Rameshkumar C, Wei L-L. *Tetrahedron* 2001;57:7575. (b) Mulder JA, Kurtz KCM, Hsung RP. *Synlett* 2003:1379. (c) Katritzky AR, Jiang R, Singh SK. *Heterocycles* 2004;63:1455.
6. For chemistry of ynamides in the last two years, see: (a) Couty S, Liegault B, Meyer C, Cossy J. *Tetrahedron* 2009;65 ASAP. (b) Deweerdt K, Birkedal H, Ruhland T, Skrydstrup T. *Org. Lett* 2009;11:221. [PubMed: 19035838] (c) Dooleweerd K, Birkedal H, Ruhland T, Skrydstrup T. *J. Org. Chem* 2008;73:9447. (d) Saito N, Katayama T, Sato Y. *Org. Lett* 2008;10:3829. [PubMed: 18681448] (e) Yasui H, Yorimitsu H, Oshima K. *Bull. Chem. Soc. Jpn* 2008;81:373. (f) Yasui H, Yorimitsu H, Oshima K. *Chem. Lett* 2008;37:40. (g) Istrate FM, Buzas AK, Jurberg ID, Odabachian Y, Gagosz F. *Org. Lett* 2008;10:925. [PubMed: 18247498] (h) Martínez-Esperón MF, Rodríguez D, Castedo L, Saá C. *Tetrahedron* 2008;64:3674. (i) Hamada T, Ye X, Stahl SS. *J. Am. Chem. Soc* 2008;130:833. [PubMed: 18166058] (j) Yavari I, Sabbaghan M, Hosseini N, Hossaini Z. *Synlett* 2007;20:3172. (k) Hashimi ASK, Salathe R, Frey W. *Synlett* 2007:1763. (l) Rodríguez D, Martínez-Esperón MF, Castedo L, Saá C. *Synlett* 2007:1963. (m) Couty S, Meyer C, Cossy J. *Synlett* 2007:2819. (n) Movassaghi M, Hill MD, Ahmad OK. *J. Am. Chem. Soc* 2007;129:10096. [PubMed: 17663557] (o) Tanaka K, Takeishi K. *Synthesis* 2007:2920. (p) Kohnen AL, Dunetz JR, Danheiser RL. *Organic Syn* 2007;84:88.
7. (a) Al-Rashid ZF, Johnson WL, Hsung RP, Wei Y, Yao P-Y, Liu R, Zhao K. *J. Org. Chem* 2008;73:8780. [PubMed: 18937407] (b) Yao P-Y, Zhang Y, Hsung RP, Zhao K. *Org. Lett* 2008;10:4275. [PubMed: 18754591] (c) Zhang X, Hsung RP, Li H, Zhang Y, Johnson WL, Figueroa R. *Org. Lett* 2008;10:3477. [PubMed: 18613692] (d) Al-Rashid ZF, Hsung RP. *Org. Lett* 2008;10:661. [PubMed: 18198881] (e) Oppenheimer J, Hsung RP, Figueroa R, Johnson WL. *Org. Lett* 2007;9:3969. [PubMed: 17764192] (f) You L, Al-Rashid ZF, Figueroa R, Ghosh SK, Li G, Lu T, Hsung RP. *Synlett* 2007:1656. (g) Li H, You L, Zhang X, Johnson WL, Figueroa R, Hsung RP. *Heterocycles* 2007;74:553. (h) Sagamanova IK, Kurtz KCM, Hsung RP. *Organic Syn* 2007;84:359. (i) Oppenheimer J, Johnson WL, Tracey MR, Hsung RP, Yao P-Y, Liu R, Zhao K. *Org. Lett* 2007;9:2361. [PubMed: 17489599]
8. Wu P, Feldman AK, Nugent AK, Hawker CJ, Scheel A, Voit B, Pyun J, Frechet JMJ, Sharpless KB, Fokin VV. *Angew. Chem., Int. Ed* 2004;43:3928.
9. Zhang X, Hsung RP, Li H. *Chem. Commun* 2007:2420.


10. For related studies on these triazolyl copper intermediates, see: (a)Gerard B, Ryan J, Beeler AB, Porco JA Jr. *Tetrahedron* 2006;62:6405. (b)Wu YM, Deng J, Li Y, Chen Q-Y. *Synthesis* 2005:1314. (c) Cassidy MP, Raushel J, Fokin VV. *Angew. Chem., Int. Ed* 2006;45:3154. see footnote 11.
11. For intermolecular additions, see: (a)Bae I, Han H, Chang S. *J. Am. Soc. Chem* 2005;127:2038. (b) Cho SH, Yoo EJ, Bae I, Chang S. *J. Am. Chem. Soc* 2005;127:16046. [PubMed: 16287290] (c)Yoo EJ, Bae I, Cho SH, Han H, Chang S. *Org. Lett* 2006;8:1347. [PubMed: 16562888] (d)Kim SH, Jung DY, Chang S. *J. Org. Chem* 2007;72:9769. [PubMed: 17979288] (e)Cho SH, Chang S. *Angew. Chem., Int. Ed* 2008;47:2836. (f)Kim J, Lee SY, Lee J, Do Y, Chang S. *J. Org. Chem* 2008;73:9454. (g)Yoo EJ, Ahlquist M, Bae I, Sharpless KB, Fokin VV, Chang S. *J. Org. Chem* 2008;73:5520. [PubMed: 18557650]
12. For an intramolecular addition, see: Chang S, Lee M, Jung DY, Yoo EJ, Cho SH, Han SK. *J. Am. Soc. Chem* 2006;128:12366.
13. For a study using ynamides, see: Kim JY, Kim SH, Chang S. *Tetrahedron Lett* 2008;49:1745.
14. For other leading examples of trapping complexes such as **3**, see: (a)Cui S-L, Lin X-F, Wang Y-G. *Org. Lett* 2006;8:4517. [PubMed: 16986939] (b)Xu X, Cheng D, Li J, Guo H, Yan J. *Org. Lett* 2007;9:1585. [PubMed: 17381100] (c)Jin Y, Fu H, Yin Y, Jiang Y, Zhao Y. *Synlett* 2007:901. (d) Cui S-L, Wang J, Wang Y-G. *Org. Lett* 2007;9:5023. [PubMed: 17979278] (e)Cui S-L, Wang J, Wang Y-G. *Org. Lett* 2008;10:1267. [PubMed: 18284250] For an earlier study on trapping of ynamido-lithium complexes, see: (f)Fromont C, Masson S. *Tetrahedron* 1999;55:5405.
15. Greenhill JV, Lue P. *Prog. Med. Chem* 1993;30:203. [PubMed: 7905649]
16. For a leading review on amidine derivatives serving as selective muscarinic agonists in the treatment of Alzheimer's diseases, see: Messer WS Jr, Dunbar PG. *Muscarinic Agonists and the Treatment of Alzheimer's Disease* 1996:131–153.153
17. Dunn, PJ. *Compreh. Org. Funct. Group Transform. II. Katritzky, Alan R.; Taylor, Richard JK., editors. Vol. Vol. 5. Sandwich, UK: Amidines and N-Substituted Amidines. Pfizer Global Research and Development; 2005. p. 655-699.*
18. For recent examples of amidine synthesis, see: (a)Yu RT, Rovis T. *J. Am. Chem. Soc* 2008;130:3262. [PubMed: 18302377] (b)Wang J, Xu F, Cai T, Shen Q. *Org. Lett* 2008;10:445. [PubMed: 18173276] (c)Malik H, Frederic B, Alexandre M, Jean-Jacques B. *Org. Biom. Chem* 2006;4:3142. (d)Katritzky AR, Cai C, Singh SK. *J. Org. Chem* 2006;71:3375. [PubMed: 16626116] (e)Kumagai N, Matsunaga S, Shibasaki M. *Angew. Chem., Int. Ed* 2004;43:478.
19. See Supporting Information. Based on NOE experiments [see Supporting Information for details], these amidines adopt an *E*-geometry with respect to the C=N bond.
20. For a leading reference on xantphos, see: Kranenburg M, van der Burgt YEM, Kamer PCJ, van Leeuwen PWNM. *Organometallics* 1995;14:3081.
21. For leading references on X-phos, see: (a)Huang X, Anderson KW, Zim D, Jiang L, Klapars A, Buchwald SL. *J. Am. Chem. Soc* 2003;125:6653. [PubMed: 12769573] (b)Barder TE, Buchwald SL. *J. Am. Chem. Soc* 2007;129:12003. [PubMed: 17850080]
22. As shown below, a non-palladium involved pathway would entail an *aza*-Claisen type of rearrangement followed by trapping of the allylketenimine intermediate **i** with an external amine. However, while this pathway is indeed a possibility, it requires much higher temperature and longer reaction time. When carried out at 65 °C to 80 °C in THF, the reaction was sluggish and slow. For a recent account on a related thermal transformation using ynoyl ethers, see: Sosa JR, Tudjarian AA, Minehan TG. *Org. Lett* 2008;10:5091. [PubMed: 18847213]
23. For leading reviews on Claisen rearrangements, see: (a)Hill RK, Morrison JD. *Asymmetric Synthesis*. 1984New YorkAcademic Press (b)Wipf P, Trost BM, Fleming I. *Comprehensive Organic Synthesis* 1991;Vol. 5OxfordPergamon Press:827.
24. Because of their basicity, polarity, and/or volatility, the respective allyl amine byproducts [R<sub>2</sub>N-CH<sub>2</sub>CH=CH<sub>2</sub>] from de-allylation were difficult to isolate. However, we were able to isolate the following allylated amine **ii** when using piperizine.
25. For a leading reference on relative nucleophilicity of amines, see: Brotzel F, Chu YC, Mayr H. *J. Org. Chem* 2007;72:3679. [PubMed: 17411095]
26. Hartwig observed that in comparison with mono-dentate phosphine ligands, the usage of bidentate ligands such as xantphos leads to a much faster amidative cross-coupling. This is presumably due to

the ability of amido-type carbonyl groups to engage in tight complexation with the palladium metal. As a result, when using xantphos, its unique bite angle promotes reductive elimination. See: Fujita K-I, Yamashita M, Puschmann F, Alvarez-Falcon MM, Incarvito CD, Hartwig JF. *J. Am. Chem. Soc.* 2006;128:9044. [PubMed: 16834372]


**Figure 1.**

Secondary Amines in the Amidine Synthesis.a,b

**a.** Reaction conditions: 5.0 mol % Pd<sub>2</sub>(dba)<sub>3</sub>, 10.0 mol % of xantphos, 1.0 equiv K<sub>2</sub>CO<sub>3</sub>, 3.0 equiv R<sub>2</sub>NH, THF [*conc* = 0.05 M], 65 °C, 1.5–6 h. **b.** Isolated yields. **c.** 10.0 mol % Pd<sub>2</sub>(dba)<sub>3</sub>, 20.0 mol% of xantphos, and 5.0 equiv R<sub>2</sub>NH were used. **d.** The only successful example in using 5.0 mol % Pd(PPh<sub>3</sub>)<sub>4</sub>.




**Scheme 1.**  
Generating Ynamido-Metal Complexes.



**Scheme 2.**  
A Proposed Mechanistic Model.





**Scheme 3.**  
Pd(II) Versus Pd(0) Source.

Table 1

Effect of Equivalents of Amines and Pd(0) Sources.

entry	Pd(0)	additive [mol %]	amine equiv	time [h]	yield [%] <sup>d</sup>	8
1	Pd(PPh <sub>3</sub> ) <sub>2</sub> Cl <sub>2</sub>	--	5.0	2	92	5
2		--	3.0	2	63	24
3		--	1.0	2	44	45
4		--	1.0: syringe pump addition	2	11	73
5	Pd(PPh <sub>3</sub> ) <sub>4</sub>	--	3.0	3	0	≥95
6	Pd(dppe)Cl <sub>2</sub>	--	3.0	48	30	<5
7	Pd(dppf)Cl <sub>2</sub>	--	3.0	24	95	0
8	Pd <sub>2</sub> (dba) <sub>3</sub>	BINAP [10.0]	3.0	24	40	59
9	Pd <sub>2</sub> (dba) <sub>3</sub>	xantphos [10.0]	3.0	3	0	≥95
10	Pd <sub>2</sub> (dba) <sub>3</sub>	X-phos [10.0]	3.0	24	<5	95


Reaction scheme: C=C[N+](=O)(c1ccc(C)cc1)C + 5.0 mol % Pd(0) source + 1.0 equiv K2CO3 + c-hex-NH2 + additive -> C=C[N+](=O)(c1ccc(C)cc1)C + c-hex

Ligand structures:   
**xantphos:** C1=CC=C(C=C1)C2=CC=C(C=C2)P(=O)(C1=CC=C(C=C1))C3=CC=C(C=C3)P(=O)(C1=CC=C(C=C1))C4=CC=C(C=C4)O5C=CC=C(C=C5)C6=CC=C(C=C6)C7=CC=C(C=C7)P(=O)(C1=CC=C(C=C1))C8=CC=C(C=C8)P(=O)(C1=CC=C(C=C1))C9=CC=C(C=C9)C10=CC=C(C=C10)C11=CC=C(C=C11)C12=CC=C(C=C12)C13=CC=C(C=C13)C14=CC=C(C=C14)C15=CC=C(C=C15)C16=CC=C(C=C16)C17=CC=C(C=C17)C18=CC=C(C=C18)C19=CC=C(C=C19)C20=CC=C(C=C20)C21=CC=C(C=C21)C22=CC=C(C=C22)C23=CC=C(C=C23)C24=CC=C(C=C24)C25=CC=C(C=C25)C26=CC=C(C=C26)C27=CC=C(C=C27)C28=CC=C(C=C28)C29=CC=C(C=C29)C30=CC=C(C=C30)C31=CC=C(C=C31)C32=CC=C(C=C32)C33=CC=C(C=C33)C34=CC=C(C=C34)C35=CC=C(C=C35)C36=CC=C(C=C36)C37=CC=C(C=C37)C38=CC=C(C=C38)C39=CC=C(C=C39)C40=CC=C(C=C40)C41=CC=C(C=C41)C42=CC=C(C=C42)C43=CC=C(C=C43)C44=CC=C(C=C44)C45=CC=C(C=C45)C46=CC=C(C=C46)C47=CC=C(C=C47)C48=CC=C(C=C48)C49=CC=C(C=C49)C50=CC=C(C=C50)C51=CC=C(C=C51)C52=CC=C(C=C52)C53=CC=C(C=C53)C54=CC=C(C=C54)C55=CC=C(C=C55)C56=CC=C(C=C56)C57=CC=C(C=C57)C58=CC=C(C=C58)C59=CC=C(C=C59)C60=CC=C(C=C60)C61=CC=C(C=C61)C62=CC=C(C=C62)C63=CC=C(C=C63)C64=CC=C(C=C64)C65=CC=C(C=C65)C66=CC=C(C=C66)C67=CC=C(C=C67)C68=CC=C(C=C68)C69=CC=C(C=C69)C70=CC=C(C=C70)C71=CC=C(C=C71)C72=CC=C(C=C72)C73=CC=C(C=C73)C74=CC=C(C=C74)C75=CC=C(C=C75)C76=CC=C(C=C76)C77=CC=C(C=C77)C78=CC=C(C=C78)C79=CC=C(C=C79)C80=CC=C(C=C80)C81=CC=C(C=C81)C82=CC=C(C=C82)C83=CC=C(C=C83)C84=CC=C(C=C84)C85=CC=C(C=C85)C86=CC=C(C=C86)C87=CC=C(C=C87)C88=CC=C(C=C88)C89=CC=C(C=C89)C90=CC=C(C=C90)C91=CC=C(C=C91)C92=CC=C(C=C92)C93=CC=C(C=C93)C94=CC=C(C=C94)C95=CC=C(C=C95)C96=CC=C(C=C96)C97=CC=C(C=C97)C98=CC=C(C=C98)C99=CC=C(C=C99)C100=CC=C(C=C100)  
**X-phos:** C1=CC=C(C=C1)C2=CC=C(C=C2)P(=O)(C1=CC=C(C=C1))C3=CC=C(C=C3)P(=O)(C1=CC=C(C=C1))C4=CC=C(C=C4)O5C=CC=C(C=C5)C6=CC=C(C=C6)C7=CC=C(C=C7)C8=CC=C(C=C8)C9=CC=C(C=C9)C10=CC=C(C=C10)C11=CC=C(C=C11)C12=CC=C(C=C12)C13=CC=C(C=C13)C14=CC=C(C=C14)C15=CC=C(C=C15)C16=CC=C(C=C16)C17=CC=C(C=C17)C18=CC=C(C=C18)C19=CC=C(C=C19)C20=CC=C(C=C20)C21=CC=C(C=C21)C22=CC=C(C=C22)C23=CC=C(C=C23)C24=CC=C(C=C24)C25=CC=C(C=C25)C26=CC=C(C=C26)C27=CC=C(C=C27)C28=CC=C(C=C28)C29=CC=C(C=C29)C30=CC=C(C=C30)C31=CC=C(C=C31)C32=CC=C(C=C32)C33=CC=C(C=C33)C34=CC=C(C=C34)C35=CC=C(C=C35)C36=CC=C(C=C36)C37=CC=C(C=C37)C38=CC=C(C=C38)C39=CC=C(C=C39)C40=CC=C(C=C40)C41=CC=C(C=C41)C42=CC=C(C=C42)C43=CC=C(C=C43)C44=CC=C(C=C44)C45=CC=C(C=C45)C46=CC=C(C=C46)C47=CC=C(C=C47)C48=CC=C(C=C48)C49=CC=C(C=C49)C50=CC=C(C=C50)C51=CC=C(C=C51)C52=CC=C(C=C52)C53=CC=C(C=C53)C54=CC=C(C=C54)C55=CC=C(C=C55)C56=CC=C(C=C56)C57=CC=C(C=C57)C58=CC=C(C=C58)C59=CC=C(C=C59)C60=CC=C(C=C60)C61=CC=C(C=C61)C62=CC=C(C=C62)C63=CC=C(C=C63)C64=CC=C(C=C64)C65=CC=C(C=C65)C66=CC=C(C=C66)C67=CC=C(C=C67)C68=CC=C(C=C68)C69=CC=C(C=C69)C70=CC=C(C=C70)C71=CC=C(C=C71)C72=CC=C(C=C72)C73=CC=C(C=C73)C74=CC=C(C=C74)C75=CC=C(C=C75)C76=CC=C(C=C76)C77=CC=C(C=C77)C78=CC=C(C=C78)C79=CC=C(C=C79)C80=CC=C(C=C80)C81=CC=C(C=C81)C82=CC=C(C=C82)C83=CC=C(C=C83)C84=CC=C(C=C84)C85=CC=C(C=C85)C86=CC=C(C=C86)C87=CC=C(C=C87)C88=CC=C(C=C88)C89=CC=C(C=C89)C90=CC=C(C=C90)C91=CC=C(C=C91)C92=CC=C(C=C92)C93=CC=C(C=C93)C94=CC=C(C=C94)C95=CC=C(C=C95)C96=CC=C(C=C96)C97=CC=C(C=C97)C98=CC=C(C=C98)C99=CC=C(C=C99)C100=CC=C(C=C100)

<sup>d</sup> All are isolated yields.

Table 2


Amidine Synthesis Using Primary Amines.<sup>a</sup>

entry	primary amines
1	
2	$\text{H}_2\text{N}-R \left\{ \begin{array}{l} R = n\text{-Bu} \\ R = t\text{-Bu} \end{array} \right.$
3	

entry

primary amines


4



5

6

7




8

entry

primary amines

9



<sup>a</sup> All reactions utilized ynamide **6**, 5.0 mol % Pd(PPh<sub>3</sub>)<sub>4</sub>, 1.0 equiv K<sub>2</sub>CO<sub>3</sub>, 3.0 equiv RNH<sub>2</sub>, THF [*conc* = 0.05 M], 65 °C, 5–8 h.

<sup>b</sup> Isolated yields.

<sup>c</sup> 1.0 equiv of amine was used.

<sup>d</sup> Reaction time was 24 h.

Table 3

Ynamide Substituent Effect.

entry	ynamides	R <sup>1</sup> =	amidines	NR <sub>2</sub> =	isolated yield [%]
1	29a	TBDPS	30a	pyrrolidinyl	95
2	29b	TBS	30b	pyrrolidinyl	94
3	29c	TES	30c	pyrrolidinyl	87
4	29d	(CH <sub>2</sub> ) <sub>3</sub> OTBS	30d	c-hex-NH	41
5	29e	c-hex	30e	pyrrolidinyl	54
6	29e	c-hex	30f	c-hex-NH	69

